The Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) meeting on 2 December 2025 witnessed a notable clash between European Commission Commissioner Olivér Várhelyi and a broad coalition of EU Member States over the scope of the EU Cardiovascular Health Plan and the financial and operational implications of the Urban Wastewater Treatment Directive (UWWTD).
While Member States presented varied health priorities—from Czechia advocating an integrated screening of cardio-renal-metabolic biomarkers to Spain emphasizing prevention through lifestyle changes and whole-of-government coordination—Várhelyi confirmed a clear Commission commitment to adopt the Cardiovascular Health Plan on 16 December. The Commission's approach includes prevention, screening (with a genetic component), rehabilitation, digital tools, and addressing health inequalities. However, the Member States expressed differing levels of emphasis and flexibility, with Poland calling for broad adaptation leeway and France supporting a transversal, experimental plan.
Another fault line emerged around the pending cost study related to the UWWTD and the environmental Extended Producer Responsibility (EPR) measures. A coalition of countries including Czechia, Germany, Poland, and others raised concerns about the potential impact on medicine availability, pricing, and health system budgets. Specific worries included the high cost of wastewater treatment possibly making key antibiotics economically unviable and the risk of price increases being passed to patients, as noted by Malta and Lithuania. The Commission acknowledged these risks but maintained the study is ongoing, leaving room for possible delays or revisions to avoid limiting patient access.
This debate took place during the EPSCO Council's meeting on 2 December 2025, hosting discussions on the EU Cardiovascular Health Plan, a cost study update on the UWWTD, a Dutch proposal for a Climate and Health Strategy, and initiatives to reinforce the European Health Union (EHU).
In terms of policy proposals, the Commission was clear and concrete, pledging adoption of the Cardiovascular Health Plan with detailed measures and deadlines. Conversely, Member States provided a mix of detailed requests—such as Czechia's call for further Commission documentation and follow-up—and more general caveats about national adaptation and budget risks. This highlights a cleavage in increasing EU-level health coordination and regulation versus maintaining national sovereignty and flexibility.
Regarding the UWWTD, Member States underlined the need for proportionality in environmental regulation to safeguard medicine availability and competitiveness in pharmaceutical industries. The Commission, while supportive of environmental goals, showed willingness to reassess schedules and impacts, reflecting a tension between environmental objectives and economic risks to industry and health systems.
Stakeholders particularly affected include EU pharmaceutical producers facing possible increased operational costs due to wastewater treatment requirements, EU healthcare systems potentially strained by medicine availability and pricing concerns, EU consumers at risk of higher drug prices, and national health authorities tasked with balancing public health outcomes and budget constraints.
The debate also touched on climate-health strategy and the future of the European Health Union within the next multiannual financial framework, highlighting ongoing discussions about health funding, integration, and resilience.
Looking forward, the Commission's adoption of the Cardiovascular Health Plan in December will be closely monitored by Member States to ensure their priorities and concerns are reflected. The forthcoming UWWTD cost study update due by mid-2026 will be critical in shaping future environmental and pharmaceutical regulations, with possible adjustments to avoid unintended negative impacts on medicine supply and costs. Dialogue between the Commission and Member States will likely continue to navigate the balance between EU-level action and national prerogatives in health and environmental policies.